Clinical and Translational Oncology

, Volume 7, Issue 9, pp 404–408 | Cite as

Sobreimpresión en fracción única con braquiterapia intersticial de alta tasa en el tratamiento conservador del carcinoma de mama

  • Inmaculada Beato Tortajada
  • Jose Luis Guinot Rodríguez
  • Leoncio Arribas Alpuente
  • Manuel Aguayo Martos
  • María Carrascosa Pérez
  • Maribel Tortajada Azcutia
  • Pedro Pablo Escolar Pérez
  • María Maroñas Martín
  • Marisa Chust Vicente
  • José Luis Mengual Cloquell
  • Carmen Pesudo Ayet y Manuel Casaña Giner
Original Articles

Resumen

Introducción

Evaluamos la eficacia de la sobreimpresión del lecho quirúrgico con braquiterapia intersticial de alta tasa de dosis, en fracción única en pacientes con cáncer de mama, tratadas con tratamiento conservador, como alternativa a la sobreimpresión con electrones.

Material y métodos

Entre abril de 1999 y diciembre de 2000, hemos realizado un estudio prospectivo sobre 84 pacientes con carcinoma infiltrante de mama sometidas a cirugía conservadora, con márgenes libres, seguida de radioterapia externa sobre la mama hasta 46 Gy y una aplicación de braquiterapia con agujas en el lecho quirúrgico, dando 7 Gy al 90% con alta tasa.

Resultados

Con un seguimiento medio de 43 meses, sólo una paciente ha recaído en zona de implante siendo el control local del 98,5% Otra paciente presentó un segundo tumor en un cuadrante distinto y tres desarrollaron metástasis. La supervivencia a 5 años es del 98,7%. La toxicidad aguda ha sido mínima, con estética excelente o buena en el 95%.

Conclusiones

La braquiterapia con alta tasa en fracción única, como sobreimpresión en el tratamiento conservador del cáncer de mama, es bien tolerada, sencilla y rápida, consiguiendo un control local excelente, con buen resultado estético y una mínima toxicidad tardía.

Palabras clave

mama braquiterapia alta tasa sobreimpresión 

Single fraction boost with high dose rate interstitial brachytherapy in conservative treatment of breast carcinoma

Abstract

Introduction

We evaluated the effectiveness of interstitial high dose rate brachytherapy as a single fraction boost to the surgical bed in patients with breast cancer undergoing conservative treatment. The comparison was with the alternative of electron boost.

Materials and methods

Between April 1999 and December 2000, we conducted a prospective study of 84 patients with infiltrative breast carcinoma treated with conservative surgery, with free margins. This was followed by external radiotherapy to the breast of up to 46 Gy and one application of brachytherapy with needles inserted into the surgical bed, and administering 7 Gy to 90% with high dose rate (HDR)/

Results

With a mean follow-up of 43 months, only one patient had therapeutic failure in the implant area, and local control was 98.5%. Another patient had a 2nd tumour in a different quadrant and 3 developed metastasis. Survival at 5 years was 98.7%. Acute toxicity was minimal, with excellent or good cosmetic appearance in 95%.

Conclusions

Brachytherapy with high dose rate as single fraction boost in conservative treatment of breast carcinoma is simple, fast, well tolerated, with excellent local control, good cosmetic appearance, and with minimal late-onset toxicity.

Key words

brachytherapy high dose rate boost breast 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Bibliografía

  1. 1.
    Fisher B, Anderson S, Redmond CK, Wolmark N, Wickerham DL, Cronin WM. Reanalysis and results after 12 years of followup in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med. 1995;333:1456–61.PubMedCrossRefGoogle Scholar
  2. 2.
    Early Breast Cancer Trialists'Collaborative Group. Effects of radiotherapy and surgery in early breast cancer. An overivew of the randomized trials. N Engl J Med. 1995;333:1444–55.CrossRefGoogle Scholar
  3. 3.
    Van Dongen JA, Voogd AC, Fentiman IS, et al. Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. J Nat Cancer Inst. 2000;92:1143–50.PubMedCrossRefGoogle Scholar
  4. 4.
    Romestaing P, Lehingue Y, Carrie C, et al. Role of 10 Gy boost in the Conservative Treatment or early Breast Cancer: results of randomized Clinical Trial In Lyon, France. J Clin Oncol. 1997;15:963–8.PubMedGoogle Scholar
  5. 5.
    Pérez CA, Taylor ME, Halverson K, García D, Kuske RR, Lockett MA. Brachytherapy or electron beam boost in conservation therapy of carcinoma of the breast: a nonrandomized comparison. Int J Radiation Oncol Biol Phys. 1996;34(5):995–1007.CrossRefGoogle Scholar
  6. 6.
    Frazier RC, Kestin LL, Kini V, et al. Impact of boost technique on outcome in early-stage cancer patients treated with breast-conserving therapy Am J Clin Oncol. 2001; 24(1):26–32.PubMedCrossRefGoogle Scholar
  7. 7.
    Moreno F, Guedea F, López Y, et al. External beam irradiation plus (192) Ir implant after breast-preserving surgery in women with early breast cancer. Int J Radiation Oncol Biol Phys. 2000;48(3):757–65.CrossRefGoogle Scholar
  8. 8.
    G Miragall E, Guinot JL, Arribas L, et al. Long term results in positive margin conservative breast cancer treatment with brachytherapy. Proceedings of 10th International Branchytherapy Conference. 2000 November 11–14 Madrid.Google Scholar
  9. 9.
    Hammer J, Seewald DH, Track C, Zoidl JP, Labeck W. Breast Cancer: Primary Treatment with external-Beam Radiation Therapy and High-Dose-Rate Iridium Implantation. Radiology. 1994;193:573–7.PubMedGoogle Scholar
  10. 10.
    Hennequin C, Durdux C, Espié, M, et al. High-Dose-Rate brachytherapy for early breast cancer: an ambulatory technique. Int J Radiation Oncology Biology Phys. 1999; 45:85–90.CrossRefGoogle Scholar
  11. 11.
    Guedea F, Arribas L. Conferencia de consenso sobre la braquiterapia en cáncer de mama en estadios iniciales. Rev Oncol. 2003;5(7):413–8.Google Scholar
  12. 12.
    Manning MA, Arthur DW, Schmidt-Ullrich RK, Arnfield M, Amir C, Zwicker R. Interstitial High-Dose-Rate brachytherapy boost: the feasibility and cosmetic outcome of a fractionated outpatient delivery scheme. Int J Radiation Oncol Biol. Phys. 2000;48:1301–6.CrossRefGoogle Scholar
  13. 13.
    Bartelink H, Horiot JC, Poortmans P, et al. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med. 2001;345:1378–87.PubMedCrossRefGoogle Scholar
  14. 14.
    Vrieling C, Collette L, Fourquet A, et al. Can patient, treatment and pathology-related characteristics explain the high local recurrence rate following breast-conserving therapy in young age? European J Cancer. 2003;3:378–90.Google Scholar
  15. 15.
    Voogd AC, Nielsen M, Peterse JL, et al. Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol. 2001;19:1688–97.PubMedGoogle Scholar
  16. 16.
    Wazer DE, Schmidt-Ullrich RK, Ruthazer R, et al. Factors determining outcome for breast-conserving irradiation with margin-directed dose escalation to the tumor bed. Int J Radiation Oncol Biol Phys. 1998;40(4):851–8.CrossRefGoogle Scholar
  17. 17.
    Kurtz J. Which patients don't need a tumor-bed boost after whole-breast radiotherapy. Strahlenther Onkol. 2001; 177:33–6.PubMedCrossRefGoogle Scholar
  18. 18.
    Hughes K, Schanaper A, Berry D, et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med. 2004;351:971–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Vázquez C, Sancho MF, Campos J, et al. Tratamiento conservador en el cáncer de mama. Análisis de 451 pacientes con seguimento mínimo de 5 años. Oncología. 2000;23(2):77–84.Google Scholar

Copyright information

© FESEO 2005

Authors and Affiliations

  • Inmaculada Beato Tortajada
    • 1
  • Jose Luis Guinot Rodríguez
    • 1
  • Leoncio Arribas Alpuente
    • 1
  • Manuel Aguayo Martos
    • 1
  • María Carrascosa Pérez
    • 1
  • Maribel Tortajada Azcutia
    • 1
  • Pedro Pablo Escolar Pérez
    • 1
  • María Maroñas Martín
    • 1
  • Marisa Chust Vicente
    • 1
  • José Luis Mengual Cloquell
    • 1
  • Carmen Pesudo Ayet y Manuel Casaña Giner
    • 1
  1. 1.Instituo Valenciano de OncologíaValenciaSpain

Personalised recommendations